Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Sodium Chloride Injection/ DEMO 0,9% w/v, EMAPALUMAB
The George Institute
SEPSIS
1 trial -
Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen
NovoThirteen
SGA - small for gestational age children
1 trial -
Solution for injection in pre-filled syringe
Alphapharm Pty Ltd
Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)
1 trial -
SonoVue 8 microlitres/mL powder and solvent for dispersion for injection, CARBOPLATIN
Pari Pharma GmbH
recurrent primary supratentorial malignant brain tumors in children
1 trial -
Stellate Ganglion Block injection with ropivicane
United Therapeutics Europe Ltd
Post Traumatic Stress Disorder (PTSD)
1 trial -
Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept
Regeneron UK Limited
Thyroid Eye Disease
1 trial -
Subcutaneous injection of TAK-850
Takeda
Influenza Infection
1 trial -
Sugammadex Injection 2mg/kg
BRIGHT MINDS BIOSCIENCES INC.
Anesthesia, General
1 trial -
TAK-850 0.5 mL injection
Takeda
Influenza Infection
1 trial -
TAMBICICLIB 100 mg/10 mL, Solution for Injection, AZACITIDINE , TAMBICICLIB 100 mg/20 mL, Solution for Injection, VENETOCLAX
Istituto Gentili S.r.l.
Acute myeloid leukemia
1 trial -
TEPADINA 15 mg powder for concentrate for solution for infusion, Trecondi 5 g powder for solution for infusion, Mozobil 20 mg/ml solution for injection, Trecondi 5 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA ex vivo expanded.
Fondazione Telethon ETS
Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene
1 trial -
TIN816, Placebo to TIN816 70mg powder for solution for injection or infusion
Novartis Pharmaceuticals
Acute kidney injury
1 trial -
TNX-1300 (Injection)
BRIGHT MINDS BIOSCIENCES INC.
Cocaine Use
1 trial -
TQC2731 injection
Shanghai University of Traditional Chinese Medicine
Chronic Obstructive Pulmonary Disease
1 trial -
TQH2722 injection
Shanghai University of Traditional Chinese Medicine
Seasonal Allergic Rhinitis
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, EIK1001 solution for injection 1.0 mg/mL free base equivalent
The George Institute
Adult participants with metastatic (advanced) solid tumors.
1 trial -
The placebo will consist solely of the excipients of eblasakimab, i.e., the same formulation without the active ingredient and will be identical in appearance to eblasakimab. Pharmaceutical form: Solution for SC injection
Lacuna Pharma Pty Ltd
Atopic Dermatitis
1 trial -
Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections
The First People's Hospital of Lianyungang
Hematological Malignancy
1 trial -
Tyenne 162 mg solution for injection in pre-filled pen
Cardiff Oncology
Psoriatic Arthritis, Rheumatoid Arthritis
1 trial -
Tyenne 162 mg solution for injection in pre-filled pen
Cardiff Oncology
Psoriatic Arthritis, Rheumatoid Arthritis
1 trial -
UBT251 Injection 2.0 mg and UBT251 Injection Placebo
United Therapeutics Europe Ltd
Obesity &Amp; Overweight
1 trial -
UBT251 Injection 2.0 mg and UBT251 Injection Placebo
United Therapeutics Europe Ltd
Type 2 Diabetes Mellitus (T2DM)
1 trial -
Ubamatamab, TOCILIZUMAB, Ubamatamab, Kevzara 175 mg/ml solution for injection, CEMIPLIMAB, LIBTAYO 350 mg concentrate for solution for infusion., Sarilumab
Lacuna Pharma Pty Ltd
Fallopian Tube Cancer, Endometrial Cancer, Ovarian Cancer, Primary Peritoneal Cancer
1 trial -
VAY736, Placebo Solution for injection or infusion 0 mg/1 mL
Novartis Pharmaceuticals
Moderate to severe hidradenitis suppurativa
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources